WBR235: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{WBRQuestion |QuestionAuthor=Gerald Chi |ExamType=USMLE Step 1 |MainCategory=Pharmacology, Physiology |SubCategory=Cardiology |MainCategory=Pharmacology, Physiology |SubCateg...")
 
m (refreshing WBR questions)
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor=Gerald Chi
|QuestionAuthor=Gerald Chi (Reviewed by  {{YD}})
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Pharmacology, Physiology
|MainCategory=Physiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Pharmacology, Physiology
|MainCategory=Physiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Pharmacology, Physiology
|MainCategory=Physiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Pharmacology, Physiology
|MainCategory=Physiology
|MainCategory=Pharmacology, Physiology
|MainCategory=Physiology
|MainCategory=Physiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Pharmacology, Physiology
|MainCategory=Physiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Pharmacology, Physiology
|MainCategory=Physiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Pharmacology, Physiology
|MainCategory=Physiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Pharmacology, Physiology
|MainCategory=Physiology
|MainCategory=Pharmacology, Physiology
|MainCategory=Physiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|Prompt=A 30-year-old postdoctoral scholar in a research laboratory develops a novel agent that preferentially targets smooth muscle cells in the coronary vessels. After injecting the drug to herself, she begins to have repeated attacks of profound substernal discomfort that prompt evaluation in the emergency room. Physical examination is insignificant, vital signs are within normal range. Electrocardiogram shows modest ST-segment depression in lead I, aVL, and V1-3. Which of the following events is most likely to be produced by the drug?
|Prompt=A lab researcher develops a novel pharmacologic agent that preferentially targets smooth muscle cells in the coronary vessels. During her experiment, she accidentally sticks herself with a needle loaded with the novel agent, and she begins to have repeated attacks of profound substernal discomfort that prompt urgent evaluation in the emergency department (ED). In the ED, her vital signs are within normal range, and her physical examination is unremarkable. A 12-lead ECG demonstrates modest ST-segment elevation. Which of the following molecular events is most likely to be induced by the novel pharmacologic agent?
|Explanation=The novel agent is likely to cause vasospasm of coronary arteries that produces angina symptoms in the patient. Multiple signaling pathways are involved in modulation of contraction and relaxation of vascular smooth muscles.
|Explanation=The novel agent induces an acute vasoconstriction of the epicardial coronary arteries and may result in either near or complete arterial occlusions. Coronary artery spasm typically manifests in angina with ST-segment elevations (not depressions) on 12-lead ECG. Modulation of contraction and relaxation of vascular smooth muscles is mainly mediated by the phosphorylation and dephosphorylation of myosin light chain kinase (MLCK) and phosphatase (MLCP). In the classical muscle contraction pathway, stimuli (e.g. histamine) initially bind to Gq protein-coupled receptors located on the surface of vascular smooth muscle cells. The binding process activates phospholipase C, which mediates the synthesis of both 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 then binds to receptors on the sarcoplasmic reticulum to mediate the mobilization of stored calcium into the cytosol. As cytosolic calcium concentration increases, calcium/calmodulin complexes form and activate MLCK, which result in the phosphorylation of myosin light chain and smooth muscle contraction.
 
|AnswerA=Activation of protein kinase A
|AnswerA=Activation of protein kinase A
|AnswerAExp='''Incorrect'''<BR>Activation of protein kinase A causes phosphorylation of the myosin light chain kinase, which turns off its activity and results in vasodilation.<BR>
|AnswerAExp=Protein kinase A mediates the phosphorylation of the myosin light chain kinase and subsequently inactivates it. Myosin light chain kinase inactivation results in vasodilation.
|AnswerB=Activation of protein kinase G
|AnswerB=Activation of protein kinase G
|AnswerBExp='''Incorrect'''<BR>Activation of protein kinase G activates myosin light chain phosphatase and results in vasodilation.<BR>
|AnswerBExp=Activation of protein kinase G activates myosin light chain phosphatase. Activation of myosin light chain phosphatase results in vasodilation.
|AnswerC=Activation of phospholipase C
|AnswerC=Activation of phospholipase C
|AnswerCExp='''Correct'''<BR>PLC is induced upon ligand binding to Gq protein-coupled receptor. which results in cleavage of PIP2 into IP3 and DAG. IP3 mobilizes calcium from sarcoplasmic reticulum and raises cytoplasmic calcium concentration, while DAG activates the protein kinase C and results in vasoconstriction.<BR>
|AnswerCExp=In the classical muscle contraction pathway, stimuli (e.g. histamine) initially bind to Gq protein-coupled receptors located on the surface of vascular smooth muscle cells. The binding process activates phospholipase C, which mediates the synthesis of both 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 then binds to receptors on the sarcoplasmic reticulum to mediate the mobilization of stored calcium into the cytosol. As cytosolic calcium concentration increases, calcium/calmodulin complexes form and activate MLCK, which result in the phosphorylation of myosin light chain and smooth muscle contraction.
|AnswerD=Inhibition of calcium binding to the troponin C subunit
|AnswerD=Inhibition of calcium binding to the troponin C subunit
|AnswerDExp='''Incorrect'''<BR>Calcium binding to the troponin C subunit is involved in the contraction of cardiac muscles rather than smooth muscles.<BR>
|AnswerDExp=Calcium binding to the troponin C subunit is involved in the contraction of cardiac muscles rather than smooth muscles.
|AnswerE=Decreased expression of gene encoding phosphodiesterase 5
|AnswerE=Decreased expression of the gene that encodes phosphodiesterase 5
|AnswerEExp='''Incorrect'''<BR> Phosphodiesterase 5 converts cyclic GMP to 5'-GMP. Cyclic GMP activates protein kinase G and causes vasodilation.<BR>
|AnswerEExp=Phosphodiesterase 5 converts cyclic GMP to 5'-GMP. Cyclic GMP activates protein kinase G and causes vasodilation.
|EducationalObjectives=In the classical muscle contraction pathway, stimuli (e.g. histamine) initially bind to Gq protein-coupled receptors located on the surface of vascular smooth muscle cells. The binding process activates phospholipase C, which mediates the synthesis of both 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 then binds to receptors on the sarcoplasmic reticulum to mediate the mobilization of stored calcium into the cytosol. As cytosolic calcium concentration increases, calcium/calmodulin complexes form and activate MLCK, which result in the phosphorylation of myosin light chain and smooth muscle contraction.
|References=Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation. 2011;124:1774-82.<br>
Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273(5272):245-8.<br>
Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature. 1994; 372(6503):231-6.
|RightAnswer=C
|RightAnswer=C
|Approved=No
|WBRKeyword=Vasospasm, Coronary artery spasm, Muscle contraction, Pharmacologic agent, Phospholipase C, PIP2, IP3, DAG, Calcium, MLCK, MLCP, Classical muscle contraction pathway
|Approved=Yes
}}
}}

Latest revision as of 02:49, 28 October 2020

 
Author [[PageAuthor::Gerald Chi (Reviewed by Yazan Daaboul, M.D.)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Physiology
Sub Category SubCategory::Cardiology
Prompt [[Prompt::A lab researcher develops a novel pharmacologic agent that preferentially targets smooth muscle cells in the coronary vessels. During her experiment, she accidentally sticks herself with a needle loaded with the novel agent, and she begins to have repeated attacks of profound substernal discomfort that prompt urgent evaluation in the emergency department (ED). In the ED, her vital signs are within normal range, and her physical examination is unremarkable. A 12-lead ECG demonstrates modest ST-segment elevation. Which of the following molecular events is most likely to be induced by the novel pharmacologic agent?]]
Answer A AnswerA::Activation of protein kinase A
Answer A Explanation AnswerAExp::Protein kinase A mediates the phosphorylation of the myosin light chain kinase and subsequently inactivates it. Myosin light chain kinase inactivation results in vasodilation.
Answer B AnswerB::Activation of protein kinase G
Answer B Explanation AnswerBExp::Activation of protein kinase G activates myosin light chain phosphatase. Activation of myosin light chain phosphatase results in vasodilation.
Answer C AnswerC::Activation of phospholipase C
Answer C Explanation [[AnswerCExp::In the classical muscle contraction pathway, stimuli (e.g. histamine) initially bind to Gq protein-coupled receptors located on the surface of vascular smooth muscle cells. The binding process activates phospholipase C, which mediates the synthesis of both 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 then binds to receptors on the sarcoplasmic reticulum to mediate the mobilization of stored calcium into the cytosol. As cytosolic calcium concentration increases, calcium/calmodulin complexes form and activate MLCK, which result in the phosphorylation of myosin light chain and smooth muscle contraction.]]
Answer D AnswerD::Inhibition of calcium binding to the troponin C subunit
Answer D Explanation AnswerDExp::Calcium binding to the troponin C subunit is involved in the contraction of cardiac muscles rather than smooth muscles.
Answer E AnswerE::Decreased expression of the gene that encodes phosphodiesterase 5
Answer E Explanation AnswerEExp::Phosphodiesterase 5 converts cyclic GMP to 5'-GMP. Cyclic GMP activates protein kinase G and causes vasodilation.
Right Answer RightAnswer::C
Explanation [[Explanation::The novel agent induces an acute vasoconstriction of the epicardial coronary arteries and may result in either near or complete arterial occlusions. Coronary artery spasm typically manifests in angina with ST-segment elevations (not depressions) on 12-lead ECG. Modulation of contraction and relaxation of vascular smooth muscles is mainly mediated by the phosphorylation and dephosphorylation of myosin light chain kinase (MLCK) and phosphatase (MLCP). In the classical muscle contraction pathway, stimuli (e.g. histamine) initially bind to Gq protein-coupled receptors located on the surface of vascular smooth muscle cells. The binding process activates phospholipase C, which mediates the synthesis of both 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 then binds to receptors on the sarcoplasmic reticulum to mediate the mobilization of stored calcium into the cytosol. As cytosolic calcium concentration increases, calcium/calmodulin complexes form and activate MLCK, which result in the phosphorylation of myosin light chain and smooth muscle contraction.

Educational Objective: In the classical muscle contraction pathway, stimuli (e.g. histamine) initially bind to Gq protein-coupled receptors located on the surface of vascular smooth muscle cells. The binding process activates phospholipase C, which mediates the synthesis of both 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 then binds to receptors on the sarcoplasmic reticulum to mediate the mobilization of stored calcium into the cytosol. As cytosolic calcium concentration increases, calcium/calmodulin complexes form and activate MLCK, which result in the phosphorylation of myosin light chain and smooth muscle contraction.
References: Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation. 2011;124:1774-82.
Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273(5272):245-8.
Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature. 1994; 372(6503):231-6.]]

Approved Approved::Yes
Keyword WBRKeyword::Vasospasm, WBRKeyword::Coronary artery spasm, WBRKeyword::Muscle contraction, WBRKeyword::Pharmacologic agent, WBRKeyword::Phospholipase C, WBRKeyword::PIP2, WBRKeyword::IP3, WBRKeyword::DAG, WBRKeyword::Calcium, WBRKeyword::MLCK, WBRKeyword::MLCP, WBRKeyword::Classical muscle contraction pathway
Linked Question Linked::
Order in Linked Questions LinkedOrder::